Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broad-Spectrum Antiviral Activity against Influenza Strains - O'Reilly, Matthew C.; Oguin III, Thomas H.; Scott, Sarah A.; Thomas, Paul G.; Locuson, Charles W.; Morrison, Ryan D.; Daniels, J. Scott; Brown, H. Alex; Lindsley, Craig W. (ChemMedChem, 2014)
Keywords: Animals; Antiviral Agents - chemistry; Antiviral Agents - pharmacokinetics; Antiviral Agents - toxicity; antivirals; Cell Line, Tumor; Cell Survival - drug effects; Chemistry, Medicinal; Dogs; Half-Life; Humans; Imidazolidines - chemistry; Imidazolidines - pharmacokinetics; Imidazolidines - toxicity; Influenza; Influenza A Virus, H1N1 Subtype - drug effects; Influenza A Virus, H3N2 Subtype - drug effects; Influenza A Virus, H5N1 Subtype - drug effects; Influenza A Virus, H7N9 Subtype - drug effects; inhibitors; Life Sciences & Biomedicine; lipids; Madin Darby Canine Kidney Cells; Pharmacology; Pharmacology & Pharmacy; Phospholipase D - antagonists & inhibitors; Phospholipase D - metabolism; phospholipase D; PLD2; Protein Binding; Rats; Rats, Sprague-Dawley; Science & Technology; Spiro Compounds - chemistry; Spiro Compounds - pharmacokinetics; Spiro Compounds - toxicity; Structure-Activity Relationship; antivirals; inhibitors; lipids; DESIGN; PHOSPHOLIPASE-D; phospholipaseD; CHEMICAL MODULATION; PLD2; HALOPEMIDE; phospholipase D